Education
About Us
Working with TipRanks
Follow Us
Amphastar Pharmaceuticals (AMPH)
NASDAQ:AMPH
Total Valuation
Amphastar Pharmaceuticals has a market cap or net worth of $1.20B. The enterprise value is $1.65B.
Market Cap$1.20B
Enterprise Value$1.65B
Share Statistics
Amphastar Pharmaceuticals has 45,952,175 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding45,952,175
Owned by Insiders25.36%
Owned by Institutions16.51%
Financial Efficiency
Amphastar Pharmaceuticals’s return on equity (ROE) is 0.22 and return on invested capital (ROIC) is 12.28%.
Return on Equity (ROE)0.22
Return on Assets (ROA)0.10
Return on Invested Capital (ROIC)12.28%
Return on Capital Employed (ROCE)0.15
Revenue Per Employee360.93K
Profits Per Employee78.66K
Employee Count2,028
Asset Turnover0.46
Inventory Turnover2.33
Valuation Ratios
The current PE Ratio of Amphastar Pharmaceuticals is 11.5. Amphastar Pharmaceuticals’s PEG ratio is 0.73.
PE Ratio11.5
PS Ratio2.46
PB Ratio2.46
Price to Fair Value2.46
Price to FCF10.43
Price to Operating Cash Flow7.94
PEG Ratio0.73
Income Statement
In the last 12 months, Amphastar Pharmaceuticals had revenue of 731.97M and earned 159.52M in profits. Earnings per share was 3.29.
Revenue731.97M
Gross Profit373.86M
Operating Income205.42M
Pretax Income189.19M
Net Income159.52M
EBITDA277.31M
Earnings Per Share (EPS)3.29
Cash Flow
In the last 12 months, operating cash flow was 152.28M and capital expenditures -39.02M, giving a free cash flow of 113.25M billion.
Operating Cash Flow152.28M
Free Cash Flow113.25M
Free Cash Flow per Share2.46
Dividends & Yields
Amphastar Pharmaceuticals pays an annual dividend of $0.3, resulting in a dividend yield of ―
Dividend Per Share$0.3
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.66
52-Week Price Change-41.73%
50-Day Moving Average25.61
200-Day Moving Average26.02
Relative Strength Index (RSI)53.32
Average Volume (3m)439.25K
Important Dates
Amphastar Pharmaceuticals upcoming earnings date is Mar 4, 2026, After Close (Confirmed).
Last Earnings DateNov 6, 2025
Next Earnings DateMar 4, 2026
Ex-Dividend DateJun 11, 2010
Financial Position
Amphastar Pharmaceuticals as a current ratio of 3.07, with Debt / Equity ratio of 84.55%
Current Ratio3.07
Quick Ratio2.19
Debt to Market Cap0.33
Net Debt to EBITDA1.80
Interest Coverage Ratio6.77
Taxes
In the past 12 months, Amphastar Pharmaceuticals has paid 29.67M in taxes.
Income Tax29.67M
Effective Tax Rate0.16
Enterprise Valuation
Amphastar Pharmaceuticals EV to EBITDA ratio is 8.28, with an EV/FCF ratio of 13.33.
EV to Sales3.14
EV to EBITDA8.28
EV to Free Cash Flow13.33
EV to Operating Cash Flow10.77
Balance Sheet
Amphastar Pharmaceuticals has $278.64M in cash and marketable securities with $656.77M in debt, giving a net cash position of -$378.13M billion.
Cash & Marketable Securities$278.64M
Total Debt$656.77M
Net Cash-$378.13M
Net Cash Per Share-$8.23
Tangible Book Value Per Share$2.92
Margins
Gross margin is 49.36%, with operating margin of 28.06%, and net profit margin of 21.79%.
Gross Margin49.36%
Operating Margin28.06%
Pretax Margin25.85%
Net Profit Margin21.79%
EBITDA Margin37.89%
EBIT Margin30.07%
Analyst Forecast
The average price target for Amphastar Pharmaceuticals is $29.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$29.50
Price Target Upside13.42% Upside
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast-0.03%
EPS Growth Forecast-27.66%